CGRP Plasma Levels Correlate with the Clinical Evolution and Prognosis of Hospitalized Acute COVID-19 Patients
SARS-CoV-2 is the etiological agent of COVID-19, an extremely heterogenous disease that can cause severe respiratory failure and critical illness. To date, reliable biomarkers allowing for early patient stratification according to disease severity are still lacking. Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide involved in lung pathophysiology and immune modulation and is poorly investigated in the COVID-19 context. In this observational, prospective cohort study, we investigated the correlation between CGRP and clinical disease evolution in hospitalized moderate to severe COVID-19 patients. Between January and May 2021 (Italian third pandemic wave), 135 consecutive SARS-CoV-2 patients were diagnosed as being eligible for the study. Plasma CGRP level evaluation and routine laboratory tests were performed on blood samples collected at baseline and after 7 days of hospitalization. At baseline, the majority our patients had a moderate to severe clinical presentation, and higher plasma CGRP levels predicted a higher risk of in-hospital negative evolution (odds-ratio OR 2.84 [IQR 1.07-7.51]) and were correlated with pulmonary intravascular coagulopathy (OR 2.92 [IQR 1.19-7.17]). Finally, plasma CGRP levels were also correlated with plasma IP10 levels. Our data support a possible crosstalk between the lung and the neuroimmune axis, highlighting a crucial role for plasma CGRP in sustaining COVID-19-related hyperinflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Viruses - 14(2022), 10 vom: 26. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rizzi, Manuela [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2022 Date Revised 04.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v14102123 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348130848 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348130848 | ||
| 003 | DE-627 | ||
| 005 | 20231226035448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v14102123 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348130848 | ||
| 035 | |a (NLM)36298678 | ||
| 035 | |a (PII)2123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rizzi, Manuela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CGRP Plasma Levels Correlate with the Clinical Evolution and Prognosis of Hospitalized Acute COVID-19 Patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2022 | ||
| 500 | |a Date Revised 04.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-CoV-2 is the etiological agent of COVID-19, an extremely heterogenous disease that can cause severe respiratory failure and critical illness. To date, reliable biomarkers allowing for early patient stratification according to disease severity are still lacking. Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide involved in lung pathophysiology and immune modulation and is poorly investigated in the COVID-19 context. In this observational, prospective cohort study, we investigated the correlation between CGRP and clinical disease evolution in hospitalized moderate to severe COVID-19 patients. Between January and May 2021 (Italian third pandemic wave), 135 consecutive SARS-CoV-2 patients were diagnosed as being eligible for the study. Plasma CGRP level evaluation and routine laboratory tests were performed on blood samples collected at baseline and after 7 days of hospitalization. At baseline, the majority our patients had a moderate to severe clinical presentation, and higher plasma CGRP levels predicted a higher risk of in-hospital negative evolution (odds-ratio OR 2.84 [IQR 1.07-7.51]) and were correlated with pulmonary intravascular coagulopathy (OR 2.92 [IQR 1.19-7.17]). Finally, plasma CGRP levels were also correlated with plasma IP10 levels. Our data support a possible crosstalk between the lung and the neuroimmune axis, highlighting a crucial role for plasma CGRP in sustaining COVID-19-related hyperinflammation | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IP10 | |
| 650 | 4 | |a calcitonin gene-related peptide (CGRP) | |
| 650 | 4 | |a pulmonary intravascular coagulopathy | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 650 | 7 | |a Chemokine CXCL10 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Neuropeptides |2 NLM | |
| 700 | 1 | |a Tonello, Stelvio |e verfasserin |4 aut | |
| 700 | 1 | |a Morani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzi, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Casciaro, Giuseppe Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Matino, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Zecca, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Croce, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrinelli, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Vassia, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Landi, Raffaella |e verfasserin |4 aut | |
| 700 | 1 | |a Mallela, Venkata Ramana |e verfasserin |4 aut | |
| 700 | 1 | |a D'Onghia, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Minisini, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Bellan, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Castello, Luigi Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Gavelli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Avanzi, Gian Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Patrucco, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Pirisi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Colangelo, Donato |e verfasserin |4 aut | |
| 700 | 1 | |a Sainaghi, Pier Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 14(2022), 10 vom: 26. Sept. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:10 |g day:26 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v14102123 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 10 |b 26 |c 09 | ||